ELMIRON® may provide relief in as soon as 3 months.
- 61% of patients on monotherapy experienced improvement in symptoms at 3 months on therapy (n=1192)†
- In a separate, double-blind, placebo-controlled study, 38% of patients with IC taking 300 mg/day reported at 3 months a greater than 50% improvement in bladder pain compared to 18% of patients taking placebo.‡
Prescribe ELMIRON® at diagnosis, as symptom improvement is often gradual
- Clinical response may require 3 to 6 months of continuous therapy
†1192 of 2499 patients received treatment for 3 months.
‡N=128 patients in 300-mg/day group. PORIS response is based on all patients, not completers.
Important Safety Information
- Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients
- Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage
- Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp
- Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug
- Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), dizziness (1%)